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Background. This trial was conducted as part of a project that aims to enhance public understanding and use of research in
decisions about healthcare by enabling viewers to participate in research and to follow the process, through television reports
and on the web. Valerian is an herbal over-the-counter drug that is widely used for insomnia. Systematic reviews have found
inconsistent and inconclusive results about its effects. Methods. Participants were recruited through a weekly nationally
televised health program in Norway. Enrolment and data collection were over the Internet. 405 participants who were 18 to
75 years old and had insomnia completed a two week diary-keeping run-in period without treatment and were randomised
and mailed valerian or placebo tablets for two weeks. All participants and investigators were blind to treatment until after the
analysis was completed. Findings. For the primary outcome of a minimally important improvement in self-reported sleep
quality ($0.5 units on a 7 point scale), the difference between the valerian group (29%) and the placebo group (21%) was not
statistically significant (difference 7.5%; 95% CI-0.9 to 15.9; p=0.08). On the global self-assessment question at the end of the
treatment period 5.5% (95% CI 0.2 to 10.8) more participants in the valerian group perceived their sleep as better or much
better (p=0.04). There were similar trends favouring the valerian group for night awakenings (difference=6.0%, 95% CI-0.5 to
12.5) and sleep duration (difference=7.5%, 95% CI-1.0 to 16.1). There were no serious adverse events and no important or
statistically significant differences in minor adverse events. Interpretation. Based on this and previous studies, valerian
appears to be safe, but with modest beneficial effects at most on insomnia compared to placebo. The combined use of
television and the Internet in randomised trials offers opportunities to answer questions about the effects of health care
interventions and to improve public understanding and use of randomised trials. Trial Registration. Controlled-Trials.com
ISRCTN72748991
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INTRODUCTION
This trial of the effectiveness of valerian for insomnia was
conducted as part of a collaboration between the Norwegian
Knowledge Centre for the Health Services and the Norwegian
Broadcasting Corporation (NRK) television program, ‘‘Puls’’. Puls
is a weekly, nationally broadcast program about health. The study
was used as an example of a randomised trial in explaining to the
television audience some of the principles related to such studies.
To our knowledge this is the second trial conducted with this
objective [1] and one of a few clinical trials conducted entirely via
the Internet [2].
Insomnia is defined by a repeated difficulty with sleep initiation,
duration, consolidation, or quality that occurs despite adequate
time and opportunity for sleep and results in some form of daytime
impairment [3]. More than 50 epidemiological studies have shown
that one third of people in a variety of general populations have
insomnia symptoms and that 9% to 21% have insomnia with
serious daytime consequences, such as fatigue, diminished energy
and difficulty concentrating [4]. In Norway, 12% of adults have
been found to suffer from insomnia based on standard criteria
(DSM-IV) [5]. Insomnia is often co-morbid with underlying
psychiatric and medical conditions, and these conditions should be
evaluated and treated as a first measure. In this study we excluded
people who reported symptoms of secondary insomnia.
A wide range of approaches are used to treat insomnia. The most
common is prescription of hypnotics, such as benzodiazepines or
newercompoundslikezolpidem,zopicloneandeszopiclone.Ofnon-
pharmacological interventions for insomnia cognitive behaviour
therapy (CBT) seems to be the best documented [6].
Due to adverse effects [7] and the fact that long-term use of
hypnotics normally not is recommended, and the limited
availability of CBT, many insomniacs resort to non-prescribed
remedies, often based upon herbs. Valerian, in particular, is widely
promoted and available without prescription in Norway and
elsewhere for treating insomnia [8–10].
The root of valerian, a perennial herb native to North America,
Asia, and Europe, is believed to have sedative and hypnotic
properties. Multiple preparations are available, and the herb is
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(Valeriana officinalis) has been suggested for several other uses,
including anxiety, depression, menopausal symptoms and stress,
but there is limited research documenting its effects for these uses.
Valerian is among the eight most widely used herbal supplements
[10].
In this trial we tested valerian as a remedy for insomnia. Valerian
has long been advocated and used for promoting sleep. During the
last 20 years a number of clinical trials have been conducted.
Systematic reviews have found inconsistent results and wide
variation in the design of the trials [8,9,11,12]. Ten randomised
trials of valerian in adults published after 2000 are included in the
Cochrane Central Register of Controlled Trials (2007, Issue 1) and
MEDLINE (searched using PubMed on 4 April 2007 with ‘valerian’
and publication type ‘randomized controlled trial’) [2,13–21]. All of
these studies were included in one or both of the most recently
published systematic reviews of valerian [11,12].
We therefore sought to rigorously evaluate the effects of
valerian, the most commonly used herbal product to induce sleep
[22] in people with primary insomnia.
METHODS
The protocol for this trial and supporting CONSORT checklist
are available as supporting information; see Checklist S1 and
Protocol S1. The primary objective of this trial was to evaluate
whether valerian improves sleep quality compared with placebo
for people with primary insomnia. The secondary objectives were
to evaluate valerian’s effects on latency to sleep onset, number of
night awakenings, total sleep time, daytime energy level, and
global self-assessed improvement.
Inclusion and exclusion criteria
Participants had to be 18 to 75 years old and have suffered from
insomnia for more than one month, a Pittsburgh Sleep Quality
Index (PSQI) score of .5 [23], Internet access, an email address,
and to have completed a sleep diary for at least 10 days in the trial
run-in period.
We excluded people with any of the following conditions: use of
hypnotics by prescription, depression, alcohol or drug abuse,
psychotherapy within the past six months, pregnant or lactating
women or women of childbearing potential who did not use oral
contraceptives or an intrauterine device, shift workers, a history of
hypersensitivity to valerian or its constituents, or current
participation in another trial using an investigational compound.
We also excluded people who answered ‘usually’ or ‘always’ to the
following questions [24]: During the past four weeks, how often
N Did you hold your breath, have breathing pauses, or stop
breathing in your sleep?
N Did you snore loudly?
N Did you have restless or ‘‘crawling’’ feelings in your legs at night
that went away if you moved your legs?
N Did you have repeated rhythmic leg jerks or leg twitches during
your sleep?
N Did you have nightmares, or did you scream, walk, punch, or
kick in your sleep?
N Did any of the following disturb you in your sleep: Pain? Other
physical symptoms? Medications?
Recruitment and withdrawals
Information about the study was broadcast nationally in Norway
three times between 29 January and 19 February 2007. Viewers
interested in participation were invited to visit the web pages of the
study to enrol (http://sovnstudien.forskningspuls.no/).
The initial screening of potential participants was conducted
online and was automated. Potential participants could contact the
study secretariat by email or telephone if they had questions or
wanted to discuss the study in more detail. We informed potential
participants that we were not providing health care and that they
would need to contact their own physician if they became ill
during the trial. A study physician was available by telephone
throughout the trial to answer questions and provide advice if
needed.
We also informed participants that they had the right to
withdraw from the study at any time. However, we encouraged
them, once they were randomised, to complete the sleep diary for
two weeks after they received the study tablets. Participants who
withdrew from the study were asked to provide their reasons for
withdrawing. Regardless of whether participants completed the
sleep diary, we sent up to three email reminders and telephoned
participants to obtain their self-assessments of global improvement
when they took tablets compared to the two weeks without tablets.
Randomisation
We assigned an identification number to potential participants
who met the inclusion criteria and consented to participate in the
trial. After completing the sleep diary for 10 days participants were
allocated to valerian or placebo according to a pre-determined
randomisation scheme, using a computerised procedure. The
corresponding numbers had been printed on the boxes containing
the study tablets.
A pharmacy kept the randomisation list and sent the study
tablets (either valerian or placebo) as a registered letter, requiring
participants to confirm receipt by signature. Participants needed to
enter the randomisation code on the tablet box in the sleep diary
to verify receipt of the package.
Intervention
The study treatment was coated tablets containing 200 mg extract
per tablet (Valerina ForteH). The manufacturer (Cederroth
International AB) stored the placebo and valerian tablets together
in a sealed room before putting them into blister packages and
shipping the tablets in boxes to the pharmacy, so that the placebo
and valerian tablets, which were identical in appearance and taste,
would smell the same.
Participants received a box with 60 tablets and instructions to
swallow three tablets every night about one hour before going to
bed for 14 days. The optimum dose of valerian is unknown [9].
The European Medicines Agency (EMEA) final proposal for Core
Data for Valerianae radix (http://www.emea.eu.int/pdfs/human/
hmpc/001499en.pdf) recommends a single dose of two to three
grams one half to one hour before bedtime with an earlier dose
during the evening if necessary. Three tablets of Valerina Forte,
correspond to 3600 mg Valeriana officinalis. This is slightly more
than the dosage recommended by EMEA, but less than the
maximum dose recommended by the manufacturer (4 tablets) and
far below the maximum recommended daily dose of nine grams.
In previous randomised trials using repeated doses, the amount
of extract taken per day has ranged from 450 to 1215 mg [9]. It
was found in N-of-1 trials that 450 mg (equivalent to 2 grams of
dry root and rhizome) was not effective, perhaps due to it being
a relatively small dose [16]. We therefore tested a larger dose to
ensure the best possibility of observing an effect and because there
is not evidence of an increased risk of side effects with the higher
dose.
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insomnia and to continue using their usual self-help strategies for
their sleeping difficulties. Upon completion of the study we asked
them to return the remaining tablets and the box to the pharmacy
using a pre-paid, return-addressed envelope.
Data collection and outcome measures
Potential participants who met the inclusion criteria and consented
to participate were automatically sent an email. They needed to
respond to this to activate their user name and password and
access their sleep diary. Participants completed a structured online
sleep diary every day during the study (figure 1), 14 days prior to
starting to take the tablets and 14 days after. Data entered into the
diary were automatically stored in a database. Participants were
asked to check that the information they entered was correct
before saving it. An automated email reminder was sent to
participants who had not completed their sleep diary by 1 p.m.
each day.
Demographic data were collected from participants at the
beginning of the study, including age, sex and education. The
PSQI, which was used to screen potential participants for
insomnia, includes 19 self-reported items and uses an algorithm
to derive a global score from components of sleep quality, sleep
latency, sleep duration, habitual sleep efficiency, sleep disturbance,
use of sleeping medication and daytime functioning [23]. Scores
range from zero to 21. Higher scores indicate more severe sleep
problems. A score of above 5 indicates a ‘‘poor’’ sleeper.
The sleep diary (figure 1) included five outcome measures that
were recorded daily: sleep onset latency, number of night
awakenings, sleep duration, sleep quality, and energy level the
following day.
These outcome measures have been used and cited in the
literature as being important measures of sleep [9,16,25–28]. The
response options that we used were modified from those used by
Coxeter and colleagues [16]. We used seven categories for all five
questions for consistency and to facilitate interpretation relative to
what has been found to be a clinically important mean difference
on 7-point scales [29]. We added an additional category at the
upper end of sleep latency and we used half-hour intervals for total
sleep time under five hours to detect what are likely to be
meaningful differences for these two outcomes, based on clinical
experience.
In addition the sleep diary included questions about adverse
events, concomitant medication, and the number of tablets taken.
At the end of the study participants were asked to assess their
sleeping problems during the two weeks when they took tablets
compared to the two week run-in period on a 7-point scale ranging
from much worse to much better. They were also asked how many
tablets they had left and were asked whether they thought the
tablets were valerian, placebo or they did not know.
Adverse events
Adverse events were defined as any undesirable experience
occurring to a participant during the study, whether or not
considered related to the study medication. Serious adverse events
were defined as an adverse experience that was fatal, life-
threatening, disabling or which resulted in-patient hospitalisation
or prolongation of hospitalisation. Unexpected adverse events
were defined as an experience not previously reported in the
product information sheet or similar documents.
Participants were asked to record all complaints that they had
each day; to indicate whether each of these was mild, moderate or
severe; and to note if a physician was seen because of the
complaint. We monitored the sleep diary for severe side-effects in
order to obtain information about potential serious adverse events
if needed. When participants registered a complaint in the sleep
diary as ‘‘severe’’, a message was automatically sent to the
secretariat and we determined whether these were serious adverse
events and whether we needed to contact the participant or
physician to obtain additional information.
Analysis
The primary outcome was the proportion of participants in each
group with an improvement in self-reported sleep quality of $0.5
units between the average score for the two weeks before and two
weeks during treatment. This was based on what we assumed
likely to be a clinically important difference, based on findings
from other 7-point scales [29]. The two proportions were
compared using a chi-square test.
Secondary analyses included comparisons of the proportion of
participants in each group with an improvement of $0.5 units
between the average score for the two weeks before and two weeks
during treatment for the other four outcome measures: sleep onset
latency, the number of awakenings, sleep duration, and daytime
energy level. These were also compared using chi-square tests. In
addition, we compared the mean change for each of the five
outcome measures using two-sample t-tests. For the participants’
global self-assessments of change in their sleeping problems we
compared the proportion of participants that reported an
improvement using two cut off points-better or much better, and
any improvement-using chi-square tests.
We conducted an exploratory analysis where we compared the
proportion of participants in each group with any improvement in
mean difference (i.e. .0) between the average score for the two
weeks before and two weeks during treatment for each of the five
variables using chi-square tests. We also conducted an exploratory
analysis using repeated measures analysis of variance for all five
outcome measures in order to reveal any difference in the profile
of the five endpoints during the intervention period taking into
account the run-in period and we evaluated whether there were
differences in effect over time.
Safety analyses included tabulation of type and frequency of all
adverse events. We compared the proportion of participants in
each group recording one or more adverse events during the
intervention compared to the run-in period using McNemar’s test
and chi-square tests for the between group comparisons.
All analyses were done on an ‘‘intention-to-treat’’ basis; i.e. all
participants who reported receiving study drugs and taking them
at least once were included. All p-values and confidence intervals
are reported without adjustments for multiple comparisons, and
have been interpreted in light of the number of comparisons that
were made. The analyses were done using SAS (Version 9.1.3.
SAS Institute Inc., Cary, NC, USA).
The randomisation code was broken in two steps. The
participants were identified as belonging to group ‘‘A’’ or ‘‘B’’
without revealing which was the valerian and placebo group. The
‘‘A’’ and ‘‘B’’ code was not broken until the primary and
secondary statistical analyses had been completed and reviewed by
the investigators.
Sample size calculations
We estimated the number of participants needed to reject the null
hypothesis (no difference between valerian and placebo) for the
primary analysis for proportions from 0.15 to 0.40 in the placebo
group and absolute improvements of 10 to 25% based on Pearson
Chi-square 2-sided tests for two proportions, with a significance
TV Trials-Valerian
PLoS ONE | www.plosone.org 3 October 2007 | Issue 10 | e1040Figure 1. Sleep diary. This is a translation of the diary, which was in Norwegian. The electronic diary included online help, a calendar indicating the
number of days completed and remaining, options for viewing graphs of each of the five outcome variables, space for personal notes, and
automated checks to ensure that the diary was completed each day and checked for correctness before being submitted. Changes could not be
made after the data were submitted. Participants could print out paper versions of the sleep diary and enter the data electronically later if they chose
to do so.
doi:10.1371/journal.pone.0001040.g001
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all participants who completed the sleep diary for at least one day
were included in all of the analyses except for global self-assessed
improvement. The calculations were performed with SAS, PROC
POWER. The estimated sample sizes ranged from 58 to 388 per
group, depending on the proportion in the placebo group and the
minimum difference considered to be important. We intended to
include 250–275 participants in each group in order to be able to
reject the null hypothesis if the difference in proportions was
between 10 and 15%.
Ethical considerations
The protocol, participant information and informed consent form
were approved by the Regional Committee for Medical Research
Ethics–Southern Norway, the Norwegian Medicines Agency and
the Norwegian Social Science Data Services. The trial was
registered and assigned an International Standard Randomised
Controlled Trial Number (ISRCTN72748991) by Current
Controlled Trials (www.controlled-trials.com) prior to commenc-
ing recruitment. The protocol is publicly available (http://www.
kunnskapssenteret.no/filer/sovnstudien_protokoll_3_1_2_2007_01_
3.pdf).
Study participants were informed that they were free to
withdraw from the study at any time and that there was no risk
associated with discontinuing taking the tablets. Information about
the study was provided to all potential participants on the web
pages. The participants could take as much time as they needed to
read and understand the information before consenting to
participate (electronically). They had the opportunity to contact
the investigators by phone or email and ask questions before
deciding whether they wanted to participate in the study. In order
to participate, potential participants had to answer several
questions to ensure that they understood the study procedures
and potential harms and benefits before they verified their consent
to participate online.
Because the study was used to educate a television audience
regarding principles of randomised trials, journalists wanted to
interview and follow some of the participants in the study. The
participants were asked upon inclusion whether they would be
interested in being contacted by a journalist. It was emphasized
that this was not a prerequisite for participation and that only two
to four participants would be contacted.
We kept a separate log of participants’ codes and names. This
database also included the electronic confirmation of each person’s
consent to take part in the study. The sleep diary was kept in
a secure zone. Each participant was able to access her or his own
sleep diary and no one else’s. The investigators had access only to
anonymous data in tables.
RESULTS
Information about the study was first broadcast on Puls on 29
January 2007. 698 eligible participants had completed the
informed consent by the end of the recruitment period, 5 March
2007 (figure 2). Of those 434 were eligible for randomisation after
completing the sleep diary for 10 days and were randomised. 405
people (202 in the valerian group and 203 in the placebo group)
subsequently filled in at least one day of the sleep diary after
starting to take the tablets and were included in the analyses. 328
participants completed the final global self-assessments of change
(164 in each group). All other analyses included all 405 people who
registered receipt of the tablets and took them for at least one day.
The two groups were similar with the exception of age (table 1).
The median score on the PSQI was 11 (range 7 to 18). The
median sleep duration for the month prior to entering the study
was six hours and 75% reported having very bad sleep quality.
The two groups also had similar results during the two-week
diary-keeping run-in period prior to randomisation (table 2). The
median quality of sleep for the 14 days prior to the intervention
was 3.9, corresponding to ‘‘average’’ on a scale from 1 (very bad)
to 7 (very good). The median on the scale for time to fall asleep
was 3.5, corresponding to approximately 30 minutes. The median
on the night awakenings scale was 2.4, corresponding to 2 or 3
times. The median on the sleep duration scale was 4.1,
corresponding to 5 to 6 hours, and the median on the energy
level scale was 3.9, corresponding to ‘‘average’’ on a scale from 1
(very unenergetic) to 7 (very energetic).
On average participants took the tablets for 13 days (median 14)
in both groups during the intervention period (mean 12.9 (SD 3.0)
for the valerian group and 13.0 (SD 3.1) for the placebo group.
89% of the valerian group and 90% of the placebo group took the
tablets for 14 or more days. Fewer than 5% in both groups took
the tablets for four or fewer days. 57 participants reported a reason
for not taking the tablets for the full 14 days. The most common
reasons were not wanting to bother anymore with the sleep diary
(14), travel or problems with access to the Internet (11), influenza
or a cold (5), no improvement or complaints attributed to the
tablets (4), and improved sleep (4).
Effectiveness of valerian
28.7% of the valerian group and 21.2% of the placebo group had
a minimally important improvement ($0.5) on the sleep quality
scale (table 3), the primary outcome measure. This difference was
not statistically significant (difference 7.5%; 95% CI-0.9 to 15.9;
p=0.08). There were similar trends favouring the valerian group
for night awakenings (difference=6.0%, 95% CI -0.5 to 12.5) and
sleep duration (difference=7.5%, 95% CI-1.0 to 16.1). There was
little difference in the average change in scores for all five outcome
measures (0.01 to 0.10 in favour of varerian) and only the
difference for night awakenings was statistically significant (mean
difference=0.09, 95% CI 0.01 to 0.18). The differences were
small and not statistically significant for any of the comparisons of
the proportions of participants with any improvement (27.6% in
favour of placebo to 5.2% in favour of valerian).
5.5% (95% CI 0.2 to 10.8) more participants in the valerian
group compared to the placebo group perceived their sleep as
better or much better on the global self-assessment question at the
end of the treatment period (p=0.04) (table 3). The difference
between the two groups for any self-assessed improvement was the
same (5.5%, 95% CI-3.7 to 14.7, p=0.25), as there was no
difference in the proportions in the two groups that indicated they
were a little better. Chi-square tests showed that the participants,
own perception of improvement on the global self-assessment did
not correspond to improvements on the five outcome measures
recorded in the sleep-diary (p,0.005).
There were no statistically significant effects of treatment for
any of the five outcome measures in the repeated measures
analysis of variance (p=0.06 for night awakenings to 0.89 for sleep
onset latency; p=0.31 for sleep quality). The mean differences
varied from day to day for all five variables from 0.01 to 0.97.
There was no apparent pattern to the differences and none of the
interactions between treatment and time were statistically
significant (p=0.11 to 0.82).
Adverse events
There were no statistically significant differences (p$0.20) between
the two groups for any type of complaint (mild, moderate or
TV Trials-Valerian
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doi:10.1371/journal.pone.0001040.g002
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intervention periods (table 4). Although 24% of participants in the
run-in period and 17% in the treatment reported ‘‘severe’’
complaints, none of the participants experienced a serious adverse
event during the study period. The majority of complaints could
be consequences of insomnia (drowsiness, tiredness, reduced
concentration, irritability, uneasiness, headache, dizziness, trem-
bling). Other complaints were unlikely to be related to valerian
(cold and influenza symptoms, eye infection, back and joint pains).
82% of the participants reported complaints during the run-in
period and 62% during the treatment periods. The difference in
the proportion of participants within each treatment group
reporting complaints during the run-in period compared to the
intervention period was statistically significant (McNemar’s
p,0.001).
Participants’ guesses about which tablets they
received
There were 8% more people in the valerian group who believed
that they had received valerian at the end of the study compared
to the placebo group (17 versus 9%), 17% fewer who believed they
had received placebo (51 versus 68%), and 9% more who
responded that they did not know (32 versus 23%). These
differences were statistically significant (p=0.004).
DISCUSSION
Our trial was nearly twice as large as any previously reported trial
of valerian. Although we did not achieve our pre-trial intended
sample size, we are able to rule out the possibility that valerian has
a large beneficial effect. The best estimate of the effect of valerian
on sleep quality, our main outcome measure, suggests that roughly
13 people with primary insomnia would need to be treated for
one additional person to experience a noticeable improvement
(NNT). However, this result was not statistically significant and we
cannot rule out either that valerian is actually worse than placebo,
or that the NNT could be as small as 6, although this appears
unlikely. There was a trend towards similar effects for night
awakenings and sleep duration, and a marginally statistically
significant effect on global self-assessed improvement of much
better or better (NNT=18, 95% CI 9 to 500). There were no
other statistically significant effects. We did not adjust for multiple
comparisons and given the number of comparisons made, it is
possible that all of the observed differences could simply reflect the
play of chance.
There is a low risk of the results being biased. The
randomisation resulted in comparable groups and only 29 people
who were randomised following the run-in period (7%) did not
take the tablets and were not included in the primary analysis or
most of the secondary analyses. Equal proportions of participants
(19%) in both groups did not answer the global self-assessment of
change question and were not included in that analysis. Although
more people in the valerian group than the placebo group thought
that they had received valerian (17 versus 9%), this most likely is
due to people who improved assuming that they were in the
valerian group and people who did not improve assuming they
were in the placebo group [30]. Of the 43 participants who
thought they received valerian 25.6% reported being better or
much better compared to 0.5% of the 195 participants who
thought they received placebo (p,0.001). There were similar
differences across the other outcomes.
Recruitment for this study was completed in one month,
data collection was completed one month after that and it was
possible to analyse the data within days, since all data were
reported online by the participants and entered directly into
a database. The time required for recruitment and follow-up
depends, of course, on the condition and treatment being studied.
However, this trial demonstrates that the combination of
television and the Internet can be effective and efficient tools
for conducting trials.
Table 1. Characteristics of the participants
......................................................................
Valerian Placebo
(N=202) (N=203)
Sex (% men) 38 40
Age
Mean (standard deviation) 45.7 (13.8) 41.8 (12.9)
Median (range) 49.0 (17–74) 42.0 (18–73)
Education
Primary school (%) 7 5
Secondary school (%) 24 28
College or university (%) 69 67
Pittsburgh Sleep Quality Index (PSQI)
Mean (standard deviation) 11.6 ( 2.7) 11.5 ( 2.6)
Median (range) 11.0 ( 7–18) 11.0 ( 7–18)
.60 minutes to fall asleep (%) 61 66
Minutes of sleep per night (N=201 and 203)
Mean (standard deviation) 312 (62) 318 (64)
Median (range) 300 (120–570) 300 ( 45–600)
Very bad sleep quality (%) 72 75
Regular use of medication–not for insomnia
(%)
50 54
*PSQI scores range from 0 to 21. Higher scores indicate more sever sleep
problems. A score of .5 indicates a ‘‘poor’’ sleeper.
doi:10.1371/journal.pone.0001040.t001
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Table 2. Run-in period results
......................................................................
Valerian (N=202) Placebo (N=203)
Sleep quality (1=very bad to 7=very good)
Mean (standard deviation) 3.89 (0.83) 3.91 (0.75)
Median (range) 3.93 (1.00–6.36) 3.93 (1.29–6.14)
asleep onset latency (1=,5 minutes to 7=$3 hours)
Mean (standard deviation) 3.61 (1.13) 3.47 (1.04)
Median (range) 3.56 (1.00–7.00) 3.36 (1.14–6.93)
Night awakenings (1=none to 7=.10 times)
Mean (standard deviation) 2.53 (0.93) 2.40 (0.80)
Median (range) 2.43 (1.00–7.00) 2.29 (1.00–6.79)
Sleep duration (1=,4 hours to 7=$8 hours)
Mean (standard deviation) 3.98 (1.04) 4.08 (0.98)
Median (range) 4.00 (1.00–6.79) 4.15 (1.14–6.21)
Energy level next day (1=very unenergetic to 7=very energetic)
Mean (standard deviation) 3.91 (0.80) 3.83 (0.68)
Median (range) 3.88 (1.71–6.50) 3.86 (1.79–6.14)
doi:10.1371/journal.pone.0001040.t002
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PLoS ONE | www.plosone.org 7 October 2007 | Issue 10 | e1040What was already known and what does this study
add
Systematic reviews have concluded that there is uncertainty about
the effectiveness of valerian [8,9,11,12]. A meta-analysis published
in 2005 that included three randomised trials with a total of 99
participants that reported sleep quality [11] a statistically non-
significant improvement with valerian (standardised mean differ-
ence 1.38, 95% CI-0.49 to 3.25) with substantial heterogeneity
among the trials (I
2=90.3%). A more recent review published in
2006 that included 16 randomised trials that reported sleep quality
found that most studies had significant methodological problems
[12]. A meta-analysis of six studies with a total of 847 participants
that reported sleep quality improvement as a dichotomous out-
come found a statistically significant improvement with valerian
(relative risk 1.8, 95% CI 1.2 to 2.9). However there was
substantial heterogeneity of the results, inclusion criteria, dose,
duration and methodological quality of these studies, as well as
evidence of publication bias. Overall, these results suggest that if
valerian has any effect on sleep quality, it is small.
A meta-analysis of three trials did not find an important
effect on sleep onset latency (weighted mean difference 21.3
minutes, 95% CI-21.4 to 18.9) and also found substantial
heterogeneity for this outcome (I
2=77.6%) [11]. A more recent
Table 3. Effectiveness results
..................................................................................................................................................
Valerian (N=202) Placebo (N=203) Difference (95% CI) P-value
Sleep quality (1=very bad to 7=very good)
- Improvement $0.5 (%) 28.7 21.2 7.5 ( 20.9 2 15.9) 0.08
- Any improvement (%) 62.9 58.1 4.7 ( 24.8 2 14.3) 0.33
- Average improvement – Mean (standard deviation) 0.23 (0.65) 0.15 (0.57) 0.08 (20.04 2 0.20) 0.21
– Median (range)] 0.15 (21.70 2 2.46) 0.07 (21.72 2 2.14)
Sleep onset latency (1=,5 minutes to 7=.3 hours)*
- Improvement$0.5 (%) 24.3 21.2 3.1 ( 25.1 2 11.2) 0.46
- Any improvement (%) 58.9 66.5 27.6 ( 217.0 2 1.8) 0.11
- Average improvement – Mean (standard deviation) 0.15 (0.63) 0.14 (0.52) 0.01 (20.11 2 0.12) 0.89
– Median (range) 0.15 (23.93 2 1.93) 0.15 (21.35 2 1.52)
Night awakenings (1=none to 7=.10 times)*
- Improvement$0.5 (%) 15.8 9.9 6.0 ( 20.5 2 12.5) 0.07
- Any improvement (%) 60.4 55.2 5.2 ( 24.4 2 14.8) 0.29
- Average improvement – Mean (standard deviation) 0.13 (0.42) 0.03 (0.41) 0.09 (0.01 2 0.18) 0.02
– Median (range) 0.07 (21.11 2 1.33) 0.05 (21.64 2 1.19)
Sleep duration (1=,4 hours to 7=.8 hours)
- Improvement $0.5 (%) 30.2 22.7 7.5 ( 21.0 2 16.1) 0.09
- Any improvement (%) 67.8 65.5 2.3 ( 26.9 2 11.5) 0.62
- Average improvement – Mean (standard deviation) 0.28 (0.64) 0.17 (0.49) 0.10 (20.01 2 0.21) 0.07
– Median (range) 0.23 (24.07 2 2.14) 0.16 (21.04 2 2.07)
Energy level next day (1=very unenergetic to 7=very energetic)
- Improvement $0.5 (%) 26.2 23.6 2.6 ( 25.8 2 11.0) 0.55
- Any improvement (%) 60.4 56.7 3.7 ( 25.8 2 13.3) 0.44
- Average improvement – Mean (standard deviation) 0.17 (0.61) 0.14 (0.62) 0.03 (20.09 2 0.15) 0.60
– Median (range) 0.14 (21.33 2 2.00) 0.10 (22.01 2 1.93)
Global self-assessment of change (N=164) (N=164)
- Much better or better (%) 9.1 3.7 5.5 ( 0.2 2 10.8) 0.04
- Any improvement (%) 26.8 21.3 5.5 ( 23.7 2 14.7) 0.25
*Although higher scores were worse for these outcomes, the results are reported in terms of improvements, consistent with the other outcomes.
doi:10.1371/journal.pone.0001040.t003
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Table 4. Adverse events
......................................................................
Valerian
(N=202)
Placebo
(N=203) Difference P-value
Mild complaints*
Run-in period (%) 74 68 5.8 0.20
Treatment period (%) 50 51 21.7 0.73
Moderate complaints*
Run-in period (%) 60 65 24.6 0.34
Treatment period (%) 48 42 5.1 0.30
Severe complaints*
Run-in period (%) 25 24 0.6 0.89
Treatment period (%) 18 16 2.1 0.58
Days with complaints
Percent 24 23 1.0 0.73
Average (SD) 3.0 (4.4) 2.9 (4.1) 0.1 0.70
*Self-reported severity
doi:10.1371/journal.pone.0001040.t004
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PLoS ONE | www.plosone.org 8 October 2007 | Issue 10 | e1040trial [22] not included in that meta-analysis reported a small
difference in sleep onset latency in favour of placebo, which was
not statistically significant (8.3 minutes, 95% CI-0.3 to 16.8 min-
utes). We also did not find any statistically significant difference for
sleep onset latency (mean improvement=0.01, 95% CI-0.11 to
0.12).
Only one randomised trial with 19 participants included in that
review [11] reported sleep duration. It found a difference of
0.8 minutes (95% CI-50.6 to 52.2), comparable with our finding of
a very small difference (mean improvement=0.10, 95% CI-0.01
to 0.21).
In summary, this randomised trial confirms that valerian is
unlikely to reduce the time it takes to fall asleep or daytime energy
level. Valerian may have a small effect on sleep quality and global
self-assessed improvement, but only a small number of people with
insomnia are likely to experience a noticeable improvement
attributable to valerian.
Implications
Valerian appears to be safe, but with very modest beneficial effects
on insomnia. The fact that valerian has any effects at all may be
a reason to explore how these effects might be enhanced. Unless
there are advances in understanding of this kind, further pragmatic
trials are unlikely to be worthwhile.
This trial was the first televised clinical trial conducted as part of
the ‘‘ForskningsPuls’’ (Research Pulse) project, which involves the
television audience in the trial and uses the trial to illustrate
principles of evaluating health care interventions. The aim of this
project is to enhance public understanding and use of randomised
trials to inform decisions about healthcare. So far as we know, it is
the second trial undertaken with this in mind [11], and it is one of
relatively few trials conducted entirely on the Internet [22].
Although there are limitations to what it is feasible to evaluate in
this way, we believe that this approach offers important
opportunities both to answer questions about the effects of health
care interventions and to improve public understanding and use of
randomised trials.
SUPPORTING INFORMATION
Protocol S1 Trial protocol
Found at: doi:10.1371/journal.pone.0001040.s001 (0.16 MB
PDF)
Checklist S1 CONSORT checklist
Found at: doi:10.1371/journal.pone.0001040.s002 (0.06 MB
DOC)
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